Overview

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Status:
Not yet recruiting
Trial end date:
2027-11-15
Target enrollment:
Participant gender:
Summary
To find a recommended dose of the combination of adagrasib and durvalumab that can be given to patients with cancers that have a KRAS G12C mutation.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
AstraZeneca
Mirati Therapeutics Inc.
Treatments:
Adagrasib
Durvalumab